{"ticker": {"uuid": "9186ff1e-c0ff-4351-ac11-c6f8b2708914", "symbol": "BRTX", "name": "BioRestorative Therapies Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Leadership shake-up at Biorestorative Therapies (NASDAQ: BRTX) and new CEO", "summary": "BioRestorative Therapies (BRTX) has undergone a significant leadership change, with President, CEO, and Chairman Lance Alstodt and CFO Robert Kristal resigning, claiming \"Good Reason\" due to an alleged Change in Control and seeking approximately $2.85 million in severance, which ", "url": "https://www.stocktitan.net/sec-filings/BRTX/8-k-bio-restorative-therapies-inc-reports-material-event-49a64d492570.html", "source_name": "Stock Titan", "published_at": "2026-07-16T21:09:48", "published_display": "16 Jul 2026 21:09", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "BioRestorative Therapies, Inc. Announces CFO Changes, Effective July 13, 2026", "summary": "BioRestorative Therapies, Inc. announced the resignation of CFO Robert Kristal, effective July 13, 2026, citing \"Good Reason\" due to a Change in Control related to Board changes in June 2026. The Board disputes the validity of the claims and has initiated an investigation into Kr", "url": "https://www.marketscreener.com/news/biorestorative-therapies-inc-announces-cfo-changes-effective-july-13-2026-ce7f5ed3d18af325", "source_name": "www.marketscreener.com", "published_at": "2026-07-16T17:30:00", "published_display": "16 Jul 2026 17:30", "sentiment": "negative", "sentiment_pct": 30, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Price to book forward of BioRestorative Therapies, Inc. \u2013 GETTEX:9OF", "summary": "This article provides the \"Price to book forward\" value for BioRestorative Therapies, Inc. (GETTEX:9OF) as part of its financial data overview on TradingView. It indicates that the current period value is available, along with change and percentage change details, and clarifies t", "url": "https://www.tradingview.com/symbols/GETTEX-9OF/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T20:13:45", "published_display": "07 Jul 2026 20:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioRestorative Therapies, Inc.'s Equity Buyback announced on August 12, 2025, has expired.", "summary": "BioRestorative Therapies, Inc. announced that its equity buyback program, originally unveiled on August 12, 2025, has officially expired. The plan concluded on June 16, 2026. This information was reported on June 15, 2026, according to S&P Capital IQ.", "url": "https://www.marketscreener.com/news/biorestorative-therapies-inc-s-equity-buyback-announced-on-august-12-2025-has-expired-ce7f5fdddc89f726", "source_name": "marketscreener.com", "published_at": "2026-07-01T12:10:43", "published_display": "01 Jul 2026 12:10", "sentiment": "negative", "sentiment_pct": 35, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of BioRestorative Therapies, Inc. \u2013 NASDAQ:BRTX", "summary": "This article displays financial information for BioRestorative Therapies, Inc. (NASDAQ: BRTX) on TradingView, specifically focusing on its enterprise value to EBITDA forward metric. The content highlights the company's financial overview within the health technology sector.", "url": "https://www.tradingview.com/symbols/NASDAQ-BRTX/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T00:41:29", "published_display": "29 Jun 2026 00:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of BioRestorative Therapies, Inc. \u2013 NASDAQ:BRTX", "summary": "This article provides access to the \"Price to book forward\" financial metric for BioRestorative Therapies, Inc. (NASDAQ: BRTX) on TradingView. It highlights that the market was closed at the time of viewing, with no trades recorded. The content primarily serves as a finance porta", "url": "https://www.tradingview.com/symbols/NASDAQ-BRTX/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T23:39:36", "published_display": "28 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of BioRestorative Therapies, Inc. \u2013 TRADEGATE:9OF", "summary": "This article provides financial information for BioRestorative Therapies, Inc. (TRADEGATE:9OF), specifically focusing on its forward price to earnings. The content indicates that for the specified period, the value is listed, but no trades were observed, and the market was closed", "url": "https://www.tradingview.com/symbols/TRADEGATE-9OF/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T08:41:30", "published_display": "28 Jun 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of BioRestorative Therapies, Inc. \u2013 NASDAQ:BRTX", "summary": "This article provides financial information for BioRestorative Therapies, Inc. (BRTX) on TradingView, specifically focusing on its enterprise value to revenue forward. It indicates the stock is listed on Nasdaq and highlights that the market is currently closed with no trades. Th", "url": "https://www.tradingview.com/symbols/NASDAQ-BRTX/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T11:10:04", "published_display": "27 Jun 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of BioRestorative Therapies, Inc. \u2013 TRADEGATE:9OF", "summary": "The article provides financial information for BioRestorative Therapies, Inc. (TRADEGATE:9OF), specifically its forward price-to-sales ratio. It's hosted on TradingView, a financial platform offering various market data and analysis tools for stocks, ETFs, crypto, and more.", "url": "https://www.tradingview.com/symbols/TRADEGATE-9OF/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T09:10:04", "published_display": "27 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of BioRestorative Therapies, Inc. \u2013 TRADEGATE:9OF", "summary": "This article provides \"Price to book forward\" information for BioRestorative Therapies, Inc. (TRADEGATE:9OF) as part of its financial data. The content primarily lists navigation and footer links from the TradingView platform, indicating that the core financial data is what the p", "url": "https://www.tradingview.com/symbols/TRADEGATE-9OF/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T04:39:42", "published_display": "27 Jun 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioRestorative Therapies, Inc. Actuals & Estimates (NASDAQ:BRTX)", "summary": "This article from TradingView provides a comprehensive overview of BioRestorative Therapies, Inc. (NASDAQ: BRTX) stock, including its current price, historical performance, analyst forecasts, and key financial metrics. It highlights the stock's significant decline over the past y", "url": "https://www.tradingview.com/symbols/NASDAQ-BRTX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T12:39:42", "published_display": "26 Jun 2026 12:39", "sentiment": "negative", "sentiment_pct": 30, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioRestorative Therapies Announces Completion of BRTX-100 Manufacturing for Phase 2 Clinical Trial", "summary": "BioRestorative Therapies has completed the manufacturing of its lead clinical product, BRTX-100, which is intended for a Phase 2 clinical trial targeting chronic lumbar disc disease (CLDD). This completion marks a significant advancement towards initiating the trial, pending all ", "url": "https://www.moomoo.com/news/post/72060211/biorestorative-therapies-announces-completion-of-brtx-100-manufacturing-for-phase", "source_name": "Moomoo", "published_at": "2026-06-26T10:39:21", "published_display": "26 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioRestorative Therapies Announces Completion of BRTX-100 Phase 2 Manufacturing, Highlighting Integrated Regenerative Biologics Platform", "summary": "BioRestorative Therapies, Inc. (Nasdaq: BRTX) has announced the successful completion of manufacturing for its BRTX-100 Phase 2 clinical trial supply. This achievement signifies a critical milestone for their lead cell therapy candidate for chronic lumbar disc disease and undersc", "url": "https://finance.yahoo.com/healthcare/articles/biorestorative-therapies-announces-completion-brtx-121500750.html", "source_name": "Market source", "published_at": "2026-06-25T22:10:40", "published_display": "25 Jun 2026 22:10", "sentiment": "positive", "sentiment_pct": 82, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioRestorative Therapies, Inc. Actuals & Estimates (DUS:9OF)", "summary": "This article provides financial actuals and estimates for BioRestorative Therapies, Inc. (9OF) traded on the Dusseldorf Stock Exchange. It includes analyst price targets, historical stock performance, earnings reports, revenue figures, net income, and current employee count, alon", "url": "https://www.tradingview.com/symbols/DUS-9OF/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T19:11:08", "published_display": "25 Jun 2026 19:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A3C9XF Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for BioRestorative Therapies, Inc. (A3C9XF), discussing analyst opinions on its future price, historical performance, and key financial metrics. It details the company's current stock price, market capitalization, earnings, revenu", "url": "https://www.tradingview.com/symbols/LS-A3C9XF/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T18:10:47", "published_display": "25 Jun 2026 18:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioRestorative finishes BRTX-100 Phase 2 supply in-house", "summary": "BioRestorative Therapies (Nasdaq:BRTX) has completed manufacturing the clinical supply for its BRTX-100 Phase 2 trial, a cell therapy aimed at chronic lumbar disc disease. This milestone showcases the company's vertically integrated regenerative medicine platform and its in-house", "url": "https://www.stocktitan.net/news/BRTX/bio-restorative-therapies-announces-completion-of-brtx-100-phase-2-qwqvxy7855on.html", "source_name": "Stock Titan", "published_at": "2026-06-25T12:41:48", "published_display": "25 Jun 2026 12:41", "sentiment": "positive", "sentiment_pct": 76, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioRestorative Therapies Announces Completion of BRTX-100", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAJBVV95cUxPcGozUkZVWVR5SlhMbkp2YWRNcjBKbEhDay13TGtoVmlEQ1lkdm5HM0phSTBiRkozaTR3NU1lcEk2Z2tXSFZFSV9LaGdCTmhwM0t4M3Z0SmFNUUI1NnhrVW9LYTlOYWwtRUJQLWY1RzUxYWhuZ0pSb01sYkM1X2VhU3g2X1hmUHZKV3RMQlhSZG55UlFxRW82Ml9POVE0ZDJfeENPbFByUXhUNGZkSlFES2NMNlB5NU9ldlNISG5ReThNQzJSOEpnaEE2UkFXMmFJSkxuUWRhZnRCamMyb0pGYnM5amtSdU1zcGtVR2k4akVjSUVFaGU4X1N2c1lWZnBTQnhzR1dqYllZeGp2aUViNkxZOFRWcUxNZGozYWdFSUpKUWpmV0R6QzVpS25uU1Jz?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioRestorative Therapies Inc (BRTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of BioRestorative Therapies Inc (BRTX), detailing its current price momentum score, support and resistance levels, and signals from various technical indicators and moving averages. While the stock is suitable for range-bound swing tradi", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-brtx/technical", "source_name": "TradingKey", "published_at": "2026-06-24T06:39:29", "published_display": "24 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biorestorative Therapies Company Profile & Introduction", "summary": "This entry is a company profile and introduction for Biorestorative Therapies. It provides an overview of the company, which is involved in Biorestorative Therapies.", "url": "https://www.moomoo.com/stock/BRTX-US/company?chain_id=Name1K9-3FXPhg.1kuo100&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A57,%22f%22%3A%22www.moomoo.com%2Fhant%2Fstock%2FCHIP.H-CA%2Ffinancials-cash-flow%22%7D", "source_name": "Moomoo", "published_at": "2026-06-19T08:40:11", "published_display": "19 Jun 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioRestorative Therapies (NASDAQ: BRTX) director Dhaliwal files clean Form 3", "summary": "Jatinder Dhaliwal, a director at BioRestorative Therapies (NASDAQ: BRTX), has filed an initial statement of beneficial ownership (Form 3) with the SEC. This filing indicates no reportable transactions or derivative positions, meaning there were no recent insider trades disclosed ", "url": "https://www.stocktitan.net/sec-filings/BRTX/form-3-bio-restorative-therapies-inc-initial-statement-of-beneficial--e821a51293fe.html", "source_name": "Stock Titan", "published_at": "2026-06-19T04:40:11", "published_display": "19 Jun 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Mika Grasso files initial Form 3 at BioRestorative (BRTX)", "summary": "Mika Grasso, a director at BioRestorative Therapies, Inc. (BRTX), has filed an initial Form 3, which is a mandatory statement of beneficial ownership for new insiders. This filing explicitly states that Grasso is a director and does not report any insider buy, sell, or other tran", "url": "https://www.stocktitan.net/sec-filings/BRTX/form-3-bio-restorative-therapies-inc-initial-statement-of-beneficial--91ccb8d452a0.html", "source_name": "Stock Titan", "published_at": "2026-06-18T20:39:01", "published_display": "18 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioRestorative Therapies Strengthens Leadership with Appointment of Healthcare Executive Zachary Smith as Vice President of Biocosmeceuticals Division to Accelerate Commercial Expansion and Strategic Growth", "summary": "BioRestorative Therapies has appointed Zachary Smith as Vice President of its Biocosmeceuticals Division to accelerate commercial expansion and strategic growth. Smith, an accomplished commercial aesthetics veteran, will lead revenue growth initiatives and sales channel expansion", "url": "https://www.manilatimes.net/2026/06/18/tmt-newswire/globenewswire/biorestorative-therapies-strengthens-leadership-with-appointment-of-healthcare-executive-zachary-smith-as-vice-president-of-biocosmeceuticals-division-to-accelerate-commercial-expansion-and-strategic-growth/2368410/amp", "source_name": "The Manila Times", "published_at": "2026-06-18T12:11:19", "published_display": "18 Jun 2026 12:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioRestorative Therapies Strengthens Leadership with", "summary": "BioRestorative Therapies, Inc. has appointed Zachary Smith as Vice President of its Biocosmeceuticals Division to accelerate commercial expansion and strategic growth in the regenerative aesthetics and advanced skincare market. Smith brings over 16 years of experience in medical ", "url": "https://www.globenewswire.com/news-release/2026/06/18/3314153/0/en/biorestorative-therapies-strengthens-leadership-with-appointment-of-healthcare-executive-zachary-smith-as-vice-president-of-biocosmeceuticals-division-to-accelerate-commercial-expa.html", "source_name": "GlobeNewswire", "published_at": "2026-06-18T08:15:00", "published_display": "18 Jun 2026 08:15", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioRestorative taps aesthetics veteran to drive skincare sales", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOQXRTR25jOWpGM1FoNUlQaHZOVVVQbDRmenV0alJYN3pMX1llSDZ0b24zSFR6RGtCTW1HUFozTUg0ckVJMHZna0lpSi1ZdU42YTBITVdJZ09ZV2tFNkpMaExXMUFCSzFyT19DV1NhZ2lxaGVmQTJBanVsd1FqUXNkWFhBQ1FGVmRNTXdQRTRKOUZoX3h1Q3EzeXMyUmRROXE5WHBKeHRLN0UxTklpRDRDSF9VblNIZEJscUZwVmFTdjI?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioRestorative Therapies (BRTX) director Katharyn Field files initial Form 3", "summary": "BioRestorative Therapies director Katharyn Field has filed an initial Statement of Beneficial Ownership on Form 3 with the SEC. This filing identifies her solely as a director, not an officer or a ten percent owner, and indicates no specific transactions or current securities hol", "url": "https://www.stocktitan.net/sec-filings/BRTX/form-3-bio-restorative-therapies-inc-initial-statement-of-beneficial--6d056ab6cb8b.html", "source_name": "Stock Titan", "published_at": "2026-06-17T20:40:20", "published_display": "17 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioRestorative Therapies Inc (BRTX) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides historical data on dividends and stock splits for BioRestorative Therapies Inc (BRTX), showing that the company has not distributed any dividends over the past five years and has no recorded stock split events. It also includes current stock information such", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-brtx/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T06:39:47", "published_display": "17 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Long term debt to total equity ratio of BioRestorative Therapies, Inc. \u2013 DUS:9OF", "summary": "This article displays the long-term debt to total equity ratio for BioRestorative Therapies, Inc. (DUS:9OF) on the TradingView platform. It highlights that the market was closed with no trades at the time of viewing. The content confirms that the financial data is 'Made by humans", "url": "https://www.tradingview.com/symbols/DUS-9OF/financials-statistics-and-ratios/long-term-debt-to-equity/", "source_name": "TradingView", "published_at": "2026-06-17T04:40:11", "published_display": "17 Jun 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioRestorative Therapies, Inc. Cash Flow \u2013 DUS:9OF", "summary": "BioRestorative Therapies, Inc. (DUS:9OF) reported Q1 2026 free cash flow of -\u20ac3.30 million. For the full year 2025, the company's free cash flow was -\u20ac9.28 million, with operating cash flow at -\u20ac9.19 million. This financial overview provides insight into the company's cash flow f", "url": "https://www.tradingview.com/symbols/DUS-9OF/financials-cash-flow/", "source_name": "TradingView", "published_at": "2026-06-16T16:39:02", "published_display": "16 Jun 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Discontinued operations of BioRestorative Therapies, Inc. \u2013 DUS:9OF", "summary": "This article briefly notes the discontinued operations of BioRestorative Therapies, Inc., traded under the ticker DUS:9OF on the Dusseldorf Stock Exchange. It provides context within a financial data platform, indicating the company's market status and the availability of financi", "url": "https://www.tradingview.com/symbols/DUS-9OF/financials-income-statement/discontinued-operations/", "source_name": "TradingView", "published_at": "2026-06-16T15:10:36", "published_display": "16 Jun 2026 15:10", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioRestorative Therapies enters $1 million revolving loan and appoints new directors", "summary": "BioRestorative Therapies (NASDAQ:BRTX) has secured a $1 million revolving loan from Bowery Group LLC for general corporate purposes, despite experiencing negative free cash flow. This financial move coincides with significant leadership changes, including the resignation of three", "url": "https://m.investing.com/news/sec-filings/biorestorative-therapies-enters-1-million-revolving-loan-and-appoints-new-directors-93CH-4740607?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-12T21:40:46", "published_display": "12 Jun 2026 21:40", "sentiment": "negative", "sentiment_pct": 36, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioRestorative (NASDAQ: BRTX) sets 3-year deal with R&D leader Silva", "summary": "BioRestorative Therapies, Inc. (NASDAQ: BRTX) has signed a new three-year employment agreement with Francisco Silva, its Vice President of Research and Development, effective June 10, 2026. Under the terms, Silva will receive an annual base salary of $575,000, be eligible for a c", "url": "https://www.stocktitan.net/sec-filings/BRTX/8-k-bio-restorative-therapies-inc-reports-material-event-37b99e555257.html", "source_name": "Stock Titan", "published_at": "2026-06-12T21:39:56", "published_display": "12 Jun 2026 21:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioRestorative Therapies stock surges on activist stake", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPc2I5NEhfc096VW9DZGhZYTRSZHlLQ29rVHA0dktqbXA0cGpJZkV2RXlGTUNvdVJTRUtMSHdWS1hISDMwRFRDSEpXOEo0RGQ1ODZRWGdJTjZaV000S0NzWTJ6UGNUR0JqSkpYSnRObEpyaHNyT09fRGItRThkMG04c0hmMXFROE5ReHVWZVpKQUpVNzI4a0ZoS29taHMxVjhKMG1UZDV3MkM2d0lqWWp6NkJIN29xM3BU?oc=5", "source_name": "Investing.com", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNTW9DYlFfMkVWMGhKTm1NSnRXeGVPb0pZWkRPbGZGWTJaczdoQWJFRDhvM3hmcjI2Z2hHaGdGcFZ3N3NsYTZSUzUxUl9QbVU4ckV5dnZnTlg2TzdKNkpjVUEtSmpJcC1VN3pKekg4dzV5M1RTc2xsY2ZvRWJUTy1uNUg5WG0tYzYzSS1scmJQVG4teEZVaHB3Wl9hbW8zRmJBbV95eExB?oc=5", "source_name": "Moomoo", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hedge fund buys 4.9% of BioRestorative, pushes AI strategy talks", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNQkJmcjRTd3VwZDBvb3k0eExiQ2FLT3ZzU3pHRGI5V296UHZYRkMxMDhqRm1JelFmVFc3NGFBZkEwaS1uYWN2OFVzRnV1ZXZuMzFEVVFENl9zbFh4Ul91QXo5ajFzWnFyMDdrVHRaTW1WV21IXzRGNWg1MjJKcGxOcXhldkdfUXp0VWY5MG1xUFVFZ3BLOW9ZekNQa0VYVU1hOW9pYndRenhUc0xMWndUX05SX1kxM3FPZ1JzR21B?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioRestorative Therapies jumps after completing Phase 2 dosing for lead spine cell therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNRU10VzlCRV9XdENsYkxWMXlfX1paT1lGYnN3Y200cEg1MFRVeFpndzVFWk1pZEJESWtRQlN3XzZwVTRCaG5CVExQX2d2TE56cE05RGtNb1BxWElZbUR6eXhrTWR6YkVaWEZRTko0SjRxVnV5dUFtZmVUOWVXOEZmVEtJbDI0NFR5cTYzblVOdk56N3l6NWJJcks3UUJvdmd2cUp2eUpoQkFOWFhnV3c1bF84LXNoMFVGNE1ZSmV0UHA?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQV2V4TVlUV3hsLWxQa2pTT2NsNFp6V1ZzeTFrSXI1VVVfUW42S0tTTFNfbGxkcUZ3VmpnRTVIUW1FUHVwUVI1UDVWRFFHU3JiVEFjMlloREY3QTZUQ3lXWTFxOUxHVkxBbjdpUXY5UnZRVFNWd2hTTkxuOXVESk5fUkZtdTRITWRfV1JrcWhfTjRlQzlkUHlDY1pLYnJKVzFMS3o0?oc=5", "source_name": "Market source", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioRestorative Therapies Completes Patient Dosing in Phase 2 Trial of BRTX-100 for Chronic Lumbar Disc Disease", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxPQkFOX1ZuemxpR1ZWZWloUE51alE5UzFsdnlnNHJxRHpvdjRQOHZpTXVPYVpkOTgxMkg0SHdveGhXZ3VCZ181WVlyN1h0bFQtNVBBWkEtM3NWSTJrQy1TdXRsZFgyNHVQVEdzQ0lxQjJiM3VLb1FzaW16aF9kTVl5alpMNUY2cUJGZnJhb0IxbVZXeld5aF8xTEF6Q0VBY0pidTR3aGRrZnN3Q2N2Mkh0d2MyY0luV0V0UlE3d3dBQjFYclhuSENyZjFWY2xZNzIwdmFWZ0RBU1kxcnM?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Makes Biorestorative Therapies (BRTX) a New Buy Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNTUlXRktxS3hYRTZ4MU1NbXNPaW5Icy1yOWlZTHdhbjd2YzlxaHVmMU5BT0lCZFkzbk1MOThWODVlWDJkRG1VeVQ4Y04wdkE4NnZiUG5CSHAyNTNtOVBtc25yMEFfZS03MDhraTMwUU9LMXFhenZONDdDbUNTY3l2ZWRRaG0ya1h3ZFFEOXNBTmlCMGdxMmwwbWl6MVUwRG1Rc0tBek8wWQ?oc=5", "source_name": "Market source", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Misses Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQOUFtdlZKRndnZmFHM09LUkdFa2FHWEtfeGRCaXQxb2VQYzFTdVlGMlNJUjVCS2VXRHk5cjA4cTdzRnBzdl9zMG1jaTRnN2lWN2NwZkp2NzJLSlB3cGhDYkZaUnE0WHZ4anJmZEdhbXZpTmg3NEFIRUhYeFpLblJJM01GZEFSTlY2VTMxLTFheUZVWjlkRGV3cHAzTGtsUTVxQ290b194TUpQREpxVUk4?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Here's Why Biorestorative Therapies (BRTX) Looks Ripe for Bottom Fishing", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOQWtKdENqZll1aFJvMGljTnRxdW54WFZ4Szl0eks3YXI1RWdFSTNjZk5zLW1KdWpZQWN4NVVkZExmNHJkQUIxSTE3dVZSM0k2bzNNcE94SjZNQnhhWW9QVGkxX1RnNTIzdm1BOERHY1AxMlFYa0hkY2dQdjM4YWFGVHVOYzZqUTFFOXhoUE9fNEJJc3pITFBWcG1walNOWTNNZkxMMG9EYzJ2SGhrZjJNOXBhZEU?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "BIORESTORATIVE THERAPIES ($BRTX) Releases Q4 2025 Earnings, Stock Rises | BRTX Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQRk94ZlhaR2hJXzNyb2s4S1pDcmdza3p0Z056Z2VSTVdOb2VBR1JjNlY4dFpMRTR5MlkyZ2hnUWQ2WF9iTmM3WDVkS1NOMG9FTnF5Zi1sUW43Rm05aWpLZmRGTzRVQ3lkNndLWHdxZGZZRndBd1VnQ0VoVkZVcGVIOUEzY1R2MEJBbXZzSjdXQ1ZwSE1yV0FjTFJvYjhOY1pCbGF1bXhBNWZIaFc2cnVqdl93?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biorestorative Therapies, Inc. (BRTX) Reports Q4 Loss, Lags Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOZTltVVNxSmszVnNJbWsxd2E3a0YzWHZ4X0FhNHlsQlZKNmxMcThONnB3cVlPNnNtM2hvRk5zZmMyUlFneFoybU9DQnpULVp5a3l6UEVGYkxZWmNSbTlpVFBKRUpDamMxdDBoRHg0RG9tSEg0S19JbWg1YnA5TnBQYU5meEVCcklCVENkY1JIOV9FN2xCQnNlOGlQdzVFN0lSbTFEeV84UFBZZw?oc=5", "source_name": "Market source", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioRestorative Therapies closes $5 million public offering By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxOY1NZNzRoTXl4ZDhtS1Q3aGRwM3ZBeFpPSXFVajJBS1JTSjE3TkdQRDhRNnVjUGVsbjgyblBoTjdoMkhqd2ZsZFZJN1dNNkVXZVp2OURSZFRPNEdvTWMzdXl4WUhqdm1UVnZfb2RRRUtFNWNIT0VVaGdqYWZDZGFRN1hrNDltdkpjdkhiSG40OVB0WVN0dGgxTzRTUWE2NGhrNlBpYXladGJiXzdJNDYwaTRaZw?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-02-14T08:00:00+00:00", "published_display": "14 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioRestorative Therapies stock plunges after $5 million public offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxPaGtrLTl1WWhLLXBBd2phWTFBU0VzWWZxTmlxYlczdVBEUTNQQzNEUGhNRGszT1NTU3dLTUtMQUk3Wm1Ua2JZZDg4cjZrYTVudW1CYTAzeDloUkRTSDFCcmZCWUdnLWc1Vm5XY2RudDNGUEFkcjV3SjhrZWFyUlk4V2pNaDdlQU1uZzR0bTFTTUpZdjNpS3E5YmFMN3V3LUVHZThsSkMzS3FjaEp1M09xSFIwSVVPTXd6QWZ3OWlIWF9panNqTU5lMEZ2LW8?oc=5", "source_name": "Investing.com", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stem cell developer BioRestorative seeks $5M for BRTX-100 trials", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQdWlya1gxT1RmQkFmeTJIQUw1U3dnYlFiQUFqWG94eTV3bWtmTzVuci05QjdxUkZDYl8wbkI3TVdoTDVhQWFSRFVaeEdUQUpUbFpRdWhTZGNSazJFTksyZk1CaWJfY0hHRHNDUklTbGVvSGFkRTZPalROUnA5bUZtM1VsLXVnRW92MTV5Y2xadE5HcVV6TEdPNXFSRnRrRnJBWTZaTlYtbklkWVZLUHJr?oc=5", "source_name": "Stock Titan", "published_at": "2026-02-11T08:00:00+00:00", "published_display": "11 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioRestorative Therapies, Inc.'s (NASDAQ:BRTX) Profit Outlook", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-05T08:00:00+00:00", "published_display": "05 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biorestorative Therapies (BRTX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFB1bFdhNWk0ZXpWRFEzdGlBZl9uVlVZSGN5dnZxcVlzS0E5aWhCMG9KSjV2R0NQQ3ppSENmYlNxUzRnOTFZV2xQWnMtWDlzZEV1VHZN?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T16:53:18+00:00", "published_display": "24 Apr 2025 16:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Leadership shake-up at Biorestorative Therapies (NASDAQ: BRTX) and new CEO", "summary": "BioRestorative Therapies (BRTX) has undergone a significant leadership change, with President, CEO, and Chairman Lance Alstodt and CFO Robert Kristal resigning, claiming \"Good Reason\" due to an alleged Change in Control and seeking approximately $2.85 million in severance, which ", "url": "https://www.stocktitan.net/sec-filings/BRTX/8-k-bio-restorative-therapies-inc-reports-material-event-49a64d492570.html", "source_name": "Stock Titan", "published_at": "2026-07-16T21:09:48", "published_display": "16 Jul 2026 21:09", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioRestorative Therapies, Inc. Announces CFO Changes, Effective July 13, 2026", "summary": "BioRestorative Therapies, Inc. announced the resignation of CFO Robert Kristal, effective July 13, 2026, citing \"Good Reason\" due to a Change in Control related to Board changes in June 2026. The Board disputes the validity of the claims and has initiated an investigation into Kr", "url": "https://www.marketscreener.com/news/biorestorative-therapies-inc-announces-cfo-changes-effective-july-13-2026-ce7f5ed3d18af325", "source_name": "www.marketscreener.com", "published_at": "2026-07-16T17:30:00", "published_display": "16 Jul 2026 17:30", "sentiment": "negative", "sentiment_pct": 30, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of BioRestorative Therapies, Inc. \u2013 GETTEX:9OF", "summary": "This article provides the \"Price to book forward\" value for BioRestorative Therapies, Inc. (GETTEX:9OF) as part of its financial data overview on TradingView. It indicates that the current period value is available, along with change and percentage change details, and clarifies t", "url": "https://www.tradingview.com/symbols/GETTEX-9OF/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T20:13:45", "published_display": "07 Jul 2026 20:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioRestorative Therapies, Inc.'s Equity Buyback announced on August 12, 2025, has expired.", "summary": "BioRestorative Therapies, Inc. announced that its equity buyback program, originally unveiled on August 12, 2025, has officially expired. The plan concluded on June 16, 2026. This information was reported on June 15, 2026, according to S&P Capital IQ.", "url": "https://www.marketscreener.com/news/biorestorative-therapies-inc-s-equity-buyback-announced-on-august-12-2025-has-expired-ce7f5fdddc89f726", "source_name": "marketscreener.com", "published_at": "2026-07-01T12:10:43", "published_display": "01 Jul 2026 12:10", "sentiment": "negative", "sentiment_pct": 35, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of BioRestorative Therapies, Inc. \u2013 NASDAQ:BRTX", "summary": "This article displays financial information for BioRestorative Therapies, Inc. (NASDAQ: BRTX) on TradingView, specifically focusing on its enterprise value to EBITDA forward metric. The content highlights the company's financial overview within the health technology sector.", "url": "https://www.tradingview.com/symbols/NASDAQ-BRTX/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T00:41:29", "published_display": "29 Jun 2026 00:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of BioRestorative Therapies, Inc. \u2013 NASDAQ:BRTX", "summary": "This article provides access to the \"Price to book forward\" financial metric for BioRestorative Therapies, Inc. (NASDAQ: BRTX) on TradingView. It highlights that the market was closed at the time of viewing, with no trades recorded. The content primarily serves as a finance porta", "url": "https://www.tradingview.com/symbols/NASDAQ-BRTX/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T23:39:36", "published_display": "28 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of BioRestorative Therapies, Inc. \u2013 TRADEGATE:9OF", "summary": "This article provides financial information for BioRestorative Therapies, Inc. (TRADEGATE:9OF), specifically focusing on its forward price to earnings. The content indicates that for the specified period, the value is listed, but no trades were observed, and the market was closed", "url": "https://www.tradingview.com/symbols/TRADEGATE-9OF/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T08:41:30", "published_display": "28 Jun 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of BioRestorative Therapies, Inc. \u2013 NASDAQ:BRTX", "summary": "This article provides financial information for BioRestorative Therapies, Inc. (BRTX) on TradingView, specifically focusing on its enterprise value to revenue forward. It indicates the stock is listed on Nasdaq and highlights that the market is currently closed with no trades. Th", "url": "https://www.tradingview.com/symbols/NASDAQ-BRTX/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T11:10:04", "published_display": "27 Jun 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of BioRestorative Therapies, Inc. \u2013 TRADEGATE:9OF", "summary": "The article provides financial information for BioRestorative Therapies, Inc. (TRADEGATE:9OF), specifically its forward price-to-sales ratio. It's hosted on TradingView, a financial platform offering various market data and analysis tools for stocks, ETFs, crypto, and more.", "url": "https://www.tradingview.com/symbols/TRADEGATE-9OF/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T09:10:04", "published_display": "27 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of BioRestorative Therapies, Inc. \u2013 TRADEGATE:9OF", "summary": "This article provides \"Price to book forward\" information for BioRestorative Therapies, Inc. (TRADEGATE:9OF) as part of its financial data. The content primarily lists navigation and footer links from the TradingView platform, indicating that the core financial data is what the p", "url": "https://www.tradingview.com/symbols/TRADEGATE-9OF/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T04:39:42", "published_display": "27 Jun 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioRestorative Therapies, Inc. Actuals & Estimates (NASDAQ:BRTX)", "summary": "This article from TradingView provides a comprehensive overview of BioRestorative Therapies, Inc. (NASDAQ: BRTX) stock, including its current price, historical performance, analyst forecasts, and key financial metrics. It highlights the stock's significant decline over the past y", "url": "https://www.tradingview.com/symbols/NASDAQ-BRTX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T12:39:42", "published_display": "26 Jun 2026 12:39", "sentiment": "negative", "sentiment_pct": 30, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioRestorative Therapies Announces Completion of BRTX-100 Manufacturing for Phase 2 Clinical Trial", "summary": "BioRestorative Therapies has completed the manufacturing of its lead clinical product, BRTX-100, which is intended for a Phase 2 clinical trial targeting chronic lumbar disc disease (CLDD). This completion marks a significant advancement towards initiating the trial, pending all ", "url": "https://www.moomoo.com/news/post/72060211/biorestorative-therapies-announces-completion-of-brtx-100-manufacturing-for-phase", "source_name": "Moomoo", "published_at": "2026-06-26T10:39:21", "published_display": "26 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioRestorative Therapies Announces Completion of BRTX-100 Phase 2 Manufacturing, Highlighting Integrated Regenerative Biologics Platform", "summary": "BioRestorative Therapies, Inc. (Nasdaq: BRTX) has announced the successful completion of manufacturing for its BRTX-100 Phase 2 clinical trial supply. This achievement signifies a critical milestone for their lead cell therapy candidate for chronic lumbar disc disease and undersc", "url": "https://finance.yahoo.com/healthcare/articles/biorestorative-therapies-announces-completion-brtx-121500750.html", "source_name": "Market source", "published_at": "2026-06-25T22:10:40", "published_display": "25 Jun 2026 22:10", "sentiment": "positive", "sentiment_pct": 82, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioRestorative Therapies, Inc. Actuals & Estimates (DUS:9OF)", "summary": "This article provides financial actuals and estimates for BioRestorative Therapies, Inc. (9OF) traded on the Dusseldorf Stock Exchange. It includes analyst price targets, historical stock performance, earnings reports, revenue figures, net income, and current employee count, alon", "url": "https://www.tradingview.com/symbols/DUS-9OF/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T19:11:08", "published_display": "25 Jun 2026 19:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A3C9XF Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for BioRestorative Therapies, Inc. (A3C9XF), discussing analyst opinions on its future price, historical performance, and key financial metrics. It details the company's current stock price, market capitalization, earnings, revenu", "url": "https://www.tradingview.com/symbols/LS-A3C9XF/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T18:10:47", "published_display": "25 Jun 2026 18:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioRestorative finishes BRTX-100 Phase 2 supply in-house", "summary": "BioRestorative Therapies (Nasdaq:BRTX) has completed manufacturing the clinical supply for its BRTX-100 Phase 2 trial, a cell therapy aimed at chronic lumbar disc disease. This milestone showcases the company's vertically integrated regenerative medicine platform and its in-house", "url": "https://www.stocktitan.net/news/BRTX/bio-restorative-therapies-announces-completion-of-brtx-100-phase-2-qwqvxy7855on.html", "source_name": "Stock Titan", "published_at": "2026-06-25T12:41:48", "published_display": "25 Jun 2026 12:41", "sentiment": "positive", "sentiment_pct": 76, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioRestorative Therapies Announces Completion of BRTX-100", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAJBVV95cUxPcGozUkZVWVR5SlhMbkp2YWRNcjBKbEhDay13TGtoVmlEQ1lkdm5HM0phSTBiRkozaTR3NU1lcEk2Z2tXSFZFSV9LaGdCTmhwM0t4M3Z0SmFNUUI1NnhrVW9LYTlOYWwtRUJQLWY1RzUxYWhuZ0pSb01sYkM1X2VhU3g2X1hmUHZKV3RMQlhSZG55UlFxRW82Ml9POVE0ZDJfeENPbFByUXhUNGZkSlFES2NMNlB5NU9ldlNISG5ReThNQzJSOEpnaEE2UkFXMmFJSkxuUWRhZnRCamMyb0pGYnM5amtSdU1zcGtVR2k4akVjSUVFaGU4X1N2c1lWZnBTQnhzR1dqYllZeGp2aUViNkxZOFRWcUxNZGozYWdFSUpKUWpmV0R6QzVpS25uU1Jz?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioRestorative Therapies Inc (BRTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of BioRestorative Therapies Inc (BRTX), detailing its current price momentum score, support and resistance levels, and signals from various technical indicators and moving averages. While the stock is suitable for range-bound swing tradi", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-brtx/technical", "source_name": "TradingKey", "published_at": "2026-06-24T06:39:29", "published_display": "24 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biorestorative Therapies Company Profile & Introduction", "summary": "This entry is a company profile and introduction for Biorestorative Therapies. It provides an overview of the company, which is involved in Biorestorative Therapies.", "url": "https://www.moomoo.com/stock/BRTX-US/company?chain_id=Name1K9-3FXPhg.1kuo100&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A57,%22f%22%3A%22www.moomoo.com%2Fhant%2Fstock%2FCHIP.H-CA%2Ffinancials-cash-flow%22%7D", "source_name": "Moomoo", "published_at": "2026-06-19T08:40:11", "published_display": "19 Jun 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioRestorative Therapies (NASDAQ: BRTX) director Dhaliwal files clean Form 3", "summary": "Jatinder Dhaliwal, a director at BioRestorative Therapies (NASDAQ: BRTX), has filed an initial statement of beneficial ownership (Form 3) with the SEC. This filing indicates no reportable transactions or derivative positions, meaning there were no recent insider trades disclosed ", "url": "https://www.stocktitan.net/sec-filings/BRTX/form-3-bio-restorative-therapies-inc-initial-statement-of-beneficial--e821a51293fe.html", "source_name": "Stock Titan", "published_at": "2026-06-19T04:40:11", "published_display": "19 Jun 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Mika Grasso files initial Form 3 at BioRestorative (BRTX)", "summary": "Mika Grasso, a director at BioRestorative Therapies, Inc. (BRTX), has filed an initial Form 3, which is a mandatory statement of beneficial ownership for new insiders. This filing explicitly states that Grasso is a director and does not report any insider buy, sell, or other tran", "url": "https://www.stocktitan.net/sec-filings/BRTX/form-3-bio-restorative-therapies-inc-initial-statement-of-beneficial--91ccb8d452a0.html", "source_name": "Stock Titan", "published_at": "2026-06-18T20:39:01", "published_display": "18 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioRestorative Therapies Strengthens Leadership with Appointment of Healthcare Executive Zachary Smith as Vice President of Biocosmeceuticals Division to Accelerate Commercial Expansion and Strategic Growth", "summary": "BioRestorative Therapies has appointed Zachary Smith as Vice President of its Biocosmeceuticals Division to accelerate commercial expansion and strategic growth. Smith, an accomplished commercial aesthetics veteran, will lead revenue growth initiatives and sales channel expansion", "url": "https://www.manilatimes.net/2026/06/18/tmt-newswire/globenewswire/biorestorative-therapies-strengthens-leadership-with-appointment-of-healthcare-executive-zachary-smith-as-vice-president-of-biocosmeceuticals-division-to-accelerate-commercial-expansion-and-strategic-growth/2368410/amp", "source_name": "The Manila Times", "published_at": "2026-06-18T12:11:19", "published_display": "18 Jun 2026 12:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioRestorative Therapies Strengthens Leadership with", "summary": "BioRestorative Therapies, Inc. has appointed Zachary Smith as Vice President of its Biocosmeceuticals Division to accelerate commercial expansion and strategic growth in the regenerative aesthetics and advanced skincare market. Smith brings over 16 years of experience in medical ", "url": "https://www.globenewswire.com/news-release/2026/06/18/3314153/0/en/biorestorative-therapies-strengthens-leadership-with-appointment-of-healthcare-executive-zachary-smith-as-vice-president-of-biocosmeceuticals-division-to-accelerate-commercial-expa.html", "source_name": "GlobeNewswire", "published_at": "2026-06-18T08:15:00", "published_display": "18 Jun 2026 08:15", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioRestorative taps aesthetics veteran to drive skincare sales", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOQXRTR25jOWpGM1FoNUlQaHZOVVVQbDRmenV0alJYN3pMX1llSDZ0b24zSFR6RGtCTW1HUFozTUg0ckVJMHZna0lpSi1ZdU42YTBITVdJZ09ZV2tFNkpMaExXMUFCSzFyT19DV1NhZ2lxaGVmQTJBanVsd1FqUXNkWFhBQ1FGVmRNTXdQRTRKOUZoX3h1Q3EzeXMyUmRROXE5WHBKeHRLN0UxTklpRDRDSF9VblNIZEJscUZwVmFTdjI?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioRestorative Therapies (BRTX) director Katharyn Field files initial Form 3", "summary": "BioRestorative Therapies director Katharyn Field has filed an initial Statement of Beneficial Ownership on Form 3 with the SEC. This filing identifies her solely as a director, not an officer or a ten percent owner, and indicates no specific transactions or current securities hol", "url": "https://www.stocktitan.net/sec-filings/BRTX/form-3-bio-restorative-therapies-inc-initial-statement-of-beneficial--6d056ab6cb8b.html", "source_name": "Stock Titan", "published_at": "2026-06-17T20:40:20", "published_display": "17 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioRestorative Therapies Inc (BRTX) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides historical data on dividends and stock splits for BioRestorative Therapies Inc (BRTX), showing that the company has not distributed any dividends over the past five years and has no recorded stock split events. It also includes current stock information such", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-brtx/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T06:39:47", "published_display": "17 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Long term debt to total equity ratio of BioRestorative Therapies, Inc. \u2013 DUS:9OF", "summary": "This article displays the long-term debt to total equity ratio for BioRestorative Therapies, Inc. (DUS:9OF) on the TradingView platform. It highlights that the market was closed with no trades at the time of viewing. The content confirms that the financial data is 'Made by humans", "url": "https://www.tradingview.com/symbols/DUS-9OF/financials-statistics-and-ratios/long-term-debt-to-equity/", "source_name": "TradingView", "published_at": "2026-06-17T04:40:11", "published_display": "17 Jun 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioRestorative Therapies, Inc. Cash Flow \u2013 DUS:9OF", "summary": "BioRestorative Therapies, Inc. (DUS:9OF) reported Q1 2026 free cash flow of -\u20ac3.30 million. For the full year 2025, the company's free cash flow was -\u20ac9.28 million, with operating cash flow at -\u20ac9.19 million. This financial overview provides insight into the company's cash flow f", "url": "https://www.tradingview.com/symbols/DUS-9OF/financials-cash-flow/", "source_name": "TradingView", "published_at": "2026-06-16T16:39:02", "published_display": "16 Jun 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Discontinued operations of BioRestorative Therapies, Inc. \u2013 DUS:9OF", "summary": "This article briefly notes the discontinued operations of BioRestorative Therapies, Inc., traded under the ticker DUS:9OF on the Dusseldorf Stock Exchange. It provides context within a financial data platform, indicating the company's market status and the availability of financi", "url": "https://www.tradingview.com/symbols/DUS-9OF/financials-income-statement/discontinued-operations/", "source_name": "TradingView", "published_at": "2026-06-16T15:10:36", "published_display": "16 Jun 2026 15:10", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioRestorative Therapies enters $1 million revolving loan and appoints new directors", "summary": "BioRestorative Therapies (NASDAQ:BRTX) has secured a $1 million revolving loan from Bowery Group LLC for general corporate purposes, despite experiencing negative free cash flow. This financial move coincides with significant leadership changes, including the resignation of three", "url": "https://m.investing.com/news/sec-filings/biorestorative-therapies-enters-1-million-revolving-loan-and-appoints-new-directors-93CH-4740607?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-12T21:40:46", "published_display": "12 Jun 2026 21:40", "sentiment": "negative", "sentiment_pct": 36, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioRestorative (NASDAQ: BRTX) sets 3-year deal with R&D leader Silva", "summary": "BioRestorative Therapies, Inc. (NASDAQ: BRTX) has signed a new three-year employment agreement with Francisco Silva, its Vice President of Research and Development, effective June 10, 2026. Under the terms, Silva will receive an annual base salary of $575,000, be eligible for a c", "url": "https://www.stocktitan.net/sec-filings/BRTX/8-k-bio-restorative-therapies-inc-reports-material-event-37b99e555257.html", "source_name": "Stock Titan", "published_at": "2026-06-12T21:39:56", "published_display": "12 Jun 2026 21:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioRestorative Therapies stock surges on activist stake", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPc2I5NEhfc096VW9DZGhZYTRSZHlLQ29rVHA0dktqbXA0cGpJZkV2RXlGTUNvdVJTRUtMSHdWS1hISDMwRFRDSEpXOEo0RGQ1ODZRWGdJTjZaV000S0NzWTJ6UGNUR0JqSkpYSnRObEpyaHNyT09fRGItRThkMG04c0hmMXFROE5ReHVWZVpKQUpVNzI4a0ZoS29taHMxVjhKMG1UZDV3MkM2d0lqWWp6NkJIN29xM3BU?oc=5", "source_name": "Investing.com", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNTW9DYlFfMkVWMGhKTm1NSnRXeGVPb0pZWkRPbGZGWTJaczdoQWJFRDhvM3hmcjI2Z2hHaGdGcFZ3N3NsYTZSUzUxUl9QbVU4ckV5dnZnTlg2TzdKNkpjVUEtSmpJcC1VN3pKekg4dzV5M1RTc2xsY2ZvRWJUTy1uNUg5WG0tYzYzSS1scmJQVG4teEZVaHB3Wl9hbW8zRmJBbV95eExB?oc=5", "source_name": "Moomoo", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hedge fund buys 4.9% of BioRestorative, pushes AI strategy talks", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNQkJmcjRTd3VwZDBvb3k0eExiQ2FLT3ZzU3pHRGI5V296UHZYRkMxMDhqRm1JelFmVFc3NGFBZkEwaS1uYWN2OFVzRnV1ZXZuMzFEVVFENl9zbFh4Ul91QXo5ajFzWnFyMDdrVHRaTW1WV21IXzRGNWg1MjJKcGxOcXhldkdfUXp0VWY5MG1xUFVFZ3BLOW9ZekNQa0VYVU1hOW9pYndRenhUc0xMWndUX05SX1kxM3FPZ1JzR21B?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioRestorative Therapies jumps after completing Phase 2 dosing for lead spine cell therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNRU10VzlCRV9XdENsYkxWMXlfX1paT1lGYnN3Y200cEg1MFRVeFpndzVFWk1pZEJESWtRQlN3XzZwVTRCaG5CVExQX2d2TE56cE05RGtNb1BxWElZbUR6eXhrTWR6YkVaWEZRTko0SjRxVnV5dUFtZmVUOWVXOEZmVEtJbDI0NFR5cTYzblVOdk56N3l6NWJJcks3UUJvdmd2cUp2eUpoQkFOWFhnV3c1bF84LXNoMFVGNE1ZSmV0UHA?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQV2V4TVlUV3hsLWxQa2pTT2NsNFp6V1ZzeTFrSXI1VVVfUW42S0tTTFNfbGxkcUZ3VmpnRTVIUW1FUHVwUVI1UDVWRFFHU3JiVEFjMlloREY3QTZUQ3lXWTFxOUxHVkxBbjdpUXY5UnZRVFNWd2hTTkxuOXVESk5fUkZtdTRITWRfV1JrcWhfTjRlQzlkUHlDY1pLYnJKVzFMS3o0?oc=5", "source_name": "Market source", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioRestorative Therapies Completes Patient Dosing in Phase 2 Trial of BRTX-100 for Chronic Lumbar Disc Disease", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxPQkFOX1ZuemxpR1ZWZWloUE51alE5UzFsdnlnNHJxRHpvdjRQOHZpTXVPYVpkOTgxMkg0SHdveGhXZ3VCZ181WVlyN1h0bFQtNVBBWkEtM3NWSTJrQy1TdXRsZFgyNHVQVEdzQ0lxQjJiM3VLb1FzaW16aF9kTVl5alpMNUY2cUJGZnJhb0IxbVZXeld5aF8xTEF6Q0VBY0pidTR3aGRrZnN3Q2N2Mkh0d2MyY0luV0V0UlE3d3dBQjFYclhuSENyZjFWY2xZNzIwdmFWZ0RBU1kxcnM?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Makes Biorestorative Therapies (BRTX) a New Buy Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNTUlXRktxS3hYRTZ4MU1NbXNPaW5Icy1yOWlZTHdhbjd2YzlxaHVmMU5BT0lCZFkzbk1MOThWODVlWDJkRG1VeVQ4Y04wdkE4NnZiUG5CSHAyNTNtOVBtc25yMEFfZS03MDhraTMwUU9LMXFhenZONDdDbUNTY3l2ZWRRaG0ya1h3ZFFEOXNBTmlCMGdxMmwwbWl6MVUwRG1Rc0tBek8wWQ?oc=5", "source_name": "Market source", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Misses Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQOUFtdlZKRndnZmFHM09LUkdFa2FHWEtfeGRCaXQxb2VQYzFTdVlGMlNJUjVCS2VXRHk5cjA4cTdzRnBzdl9zMG1jaTRnN2lWN2NwZkp2NzJLSlB3cGhDYkZaUnE0WHZ4anJmZEdhbXZpTmg3NEFIRUhYeFpLblJJM01GZEFSTlY2VTMxLTFheUZVWjlkRGV3cHAzTGtsUTVxQ290b194TUpQREpxVUk4?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why Biorestorative Therapies (BRTX) Looks Ripe for Bottom Fishing", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOQWtKdENqZll1aFJvMGljTnRxdW54WFZ4Szl0eks3YXI1RWdFSTNjZk5zLW1KdWpZQWN4NVVkZExmNHJkQUIxSTE3dVZSM0k2bzNNcE94SjZNQnhhWW9QVGkxX1RnNTIzdm1BOERHY1AxMlFYa0hkY2dQdjM4YWFGVHVOYzZqUTFFOXhoUE9fNEJJc3pITFBWcG1walNOWTNNZkxMMG9EYzJ2SGhrZjJNOXBhZEU?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BIORESTORATIVE THERAPIES ($BRTX) Releases Q4 2025 Earnings, Stock Rises | BRTX Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQRk94ZlhaR2hJXzNyb2s4S1pDcmdza3p0Z056Z2VSTVdOb2VBR1JjNlY4dFpMRTR5MlkyZ2hnUWQ2WF9iTmM3WDVkS1NOMG9FTnF5Zi1sUW43Rm05aWpLZmRGTzRVQ3lkNndLWHdxZGZZRndBd1VnQ0VoVkZVcGVIOUEzY1R2MEJBbXZzSjdXQ1ZwSE1yV0FjTFJvYjhOY1pCbGF1bXhBNWZIaFc2cnVqdl93?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biorestorative Therapies, Inc. (BRTX) Reports Q4 Loss, Lags Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOZTltVVNxSmszVnNJbWsxd2E3a0YzWHZ4X0FhNHlsQlZKNmxMcThONnB3cVlPNnNtM2hvRk5zZmMyUlFneFoybU9DQnpULVp5a3l6UEVGYkxZWmNSbTlpVFBKRUpDamMxdDBoRHg0RG9tSEg0S19JbWg1YnA5TnBQYU5meEVCcklCVENkY1JIOV9FN2xCQnNlOGlQdzVFN0lSbTFEeV84UFBZZw?oc=5", "source_name": "Market source", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioRestorative Therapies closes $5 million public offering By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxOY1NZNzRoTXl4ZDhtS1Q3aGRwM3ZBeFpPSXFVajJBS1JTSjE3TkdQRDhRNnVjUGVsbjgyblBoTjdoMkhqd2ZsZFZJN1dNNkVXZVp2OURSZFRPNEdvTWMzdXl4WUhqdm1UVnZfb2RRRUtFNWNIT0VVaGdqYWZDZGFRN1hrNDltdkpjdkhiSG40OVB0WVN0dGgxTzRTUWE2NGhrNlBpYXladGJiXzdJNDYwaTRaZw?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-02-14T08:00:00+00:00", "published_display": "14 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioRestorative Therapies stock plunges after $5 million public offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxPaGtrLTl1WWhLLXBBd2phWTFBU0VzWWZxTmlxYlczdVBEUTNQQzNEUGhNRGszT1NTU3dLTUtMQUk3Wm1Ua2JZZDg4cjZrYTVudW1CYTAzeDloUkRTSDFCcmZCWUdnLWc1Vm5XY2RudDNGUEFkcjV3SjhrZWFyUlk4V2pNaDdlQU1uZzR0bTFTTUpZdjNpS3E5YmFMN3V3LUVHZThsSkMzS3FjaEp1M09xSFIwSVVPTXd6QWZ3OWlIWF9panNqTU5lMEZ2LW8?oc=5", "source_name": "Investing.com", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stem cell developer BioRestorative seeks $5M for BRTX-100 trials", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQdWlya1gxT1RmQkFmeTJIQUw1U3dnYlFiQUFqWG94eTV3bWtmTzVuci05QjdxUkZDYl8wbkI3TVdoTDVhQWFSRFVaeEdUQUpUbFpRdWhTZGNSazJFTksyZk1CaWJfY0hHRHNDUklTbGVvSGFkRTZPalROUnA5bUZtM1VsLXVnRW92MTV5Y2xadE5HcVV6TEdPNXFSRnRrRnJBWTZaTlYtbklkWVZLUHJr?oc=5", "source_name": "Stock Titan", "published_at": "2026-02-11T08:00:00+00:00", "published_display": "11 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioRestorative Therapies, Inc.'s (NASDAQ:BRTX) Profit Outlook", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-05T08:00:00+00:00", "published_display": "05 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biorestorative Therapies (BRTX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFB1bFdhNWk0ZXpWRFEzdGlBZl9uVlVZSGN5dnZxcVlzS0E5aWhCMG9KSjV2R0NQQ3ppSENmYlNxUzRnOTFZV2xQWnMtWDlzZEV1VHZN?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T16:53:18+00:00", "published_display": "24 Apr 2025 16:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 91, "total_relevant": 56, "sentiment_summary": {"positive": 11, "negative": 9, "neutral": 36, "score": 51, "total": 56, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 77, "events": [{"event": "general", "label": "Market update", "weight": 14.3, "count": 26}, {"event": "earnings", "label": "Earnings", "weight": 8.11, "count": 17}, {"event": "deals", "label": "Deals and strategy", "weight": 2.2, "count": 4}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.65, "count": 3}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "macro", "label": "Macro sensitivity", "weight": 1.1, "count": 2}], "positive_events": 11, "negative_events": 9}, "market_context": {"has_market_context": true, "latest_close": 0.33, "latest_week": "2026-07-17", "one_week_move": -3.2, "four_week_move": -18.4, "twelve_week_move": 45.3, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.60253, "market_dynamics_buy_signal": false, "relative_strength": -67.26244, "fair_value_gap": -76.9, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 41.6495, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-3.2% over one week, -18.4% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 58, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 14}, {"label": "Market source", "count": 12}, {"label": "Stock Titan", "count": 10}, {"label": "Moomoo", "count": 3}, {"label": "Investing.com", "count": 3}, {"label": "Quiver Quantitative", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "GlobeNewswire", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 47}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 26}, {"label": "Earnings", "count": 17}, {"label": "Deals and strategy", "count": 4}, {"label": "Balance sheet", "count": 3}, {"label": "Analyst action", "count": 2}, {"label": "Macro sensitivity", "count": 2}, {"label": "Regulatory and legal", "count": 1}, {"label": "Capital return", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "51/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "47", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-3.2% over one week, -18.4% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Negative", "tone": "negative", "text": "Leadership shake-up at Biorestorative Therapies (NASDAQ: BRTX) and new CEO"}], "updated_at": "2026-07-22T08:09:04.670153+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}